Clinical Trials List
2021-07-09 - 2026-05-31
Phase III
Recruiting3
ICD-10M32.0
Drug-induced systemic lupus erythematosus
ICD-10M32.10
Systemic lupus erythematosus, organ or system involvement unspecified
ICD-10M32.11
Endocarditis in systemic lupus erythematosus
ICD-10M32.12
Pericarditis in systemic lupus erythematosus
ICD-10M32.13
Lung involvement in systemic lupus erythematosus
ICD-10M32.14
Glomerular disease in systemic lupus erythematosus
ICD-10M32.15
Tubulo-interstitial nephropathy in systemic lupus erythematosus
ICD-10M32.19
Other organ or system involvement in systemic lupus erythematosus
ICD-10M32.8
Other forms of systemic lupus erythematosus
ICD-10M32.9
Systemic lupus erythematosus, unspecified
ICD-9710.0
Systemic lupus erythematosus
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yun Chen Tsai Division of Rheumatology
- Chen-I Hsieh Division of Rheumatology
- 張哲慈 Division of Rheumatology
- TianMing Zhan Division of Rheumatology
- 謝孟儒 Division of Rheumatology
- 尤瀚華 Division of Rheumatology
- 陳彥輔 Division of Rheumatology
- Ping-Han Tsai Division of Rheumatology
- Shue-Fen Lo Division of Rheumatology
- Yao-Fan Fang Division of Rheumatology
- 黃思偉 Division of Rheumatology
- 蕭朝陽 Division of Rheumatology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 許鐘元 Division of Rheumatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
540 participants
